ClinicalTrials.gg
CompletedNCT03329781ENDOCURUpdated Apr 30, 2021

ENDOCUR - Modulation of Endotoxaemia Via Curcumin Intake in Healthy Overweight Adults

An interventional study of BCM-95 and Placebo in Overweight, sponsored by University of Glasgow. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by University of Glasgow · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Feb 2015, registered Oct 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Chronic diseases such as diabetes, cardiovascular diseases and cancer are a major burden on the Scottish population. Obesity and inflammation have strong links to these diseases. One of the mechanisms explaining the relationship between low-grade inflammation and excess weight is "endotoxaemia". We wish to study this phenomenon, when small components coming from our gut bacteria can pass into the bloodstream, raising the body's defences. Diet can modulate endotoxaemia. In this study, we propose to use curcumin, in a capsule form, to modulate endotoxaemia. Curcumin comes from turmeric, which is widely used as a spice. In this study, we want to test the effect of consuming curcumin extract to the composition of the gut microbiota, post-meal endotoxaemia, and inflammatory markers in blood.

02

Conditions studied

  • Overweight

Keywords

  • Endotoxaemia, Curcumin.
03

In context

Overweight

3,599 studies on the registry are indexed under Overweight; 852 are open to participants now.

This study's enrollment of 16 is below the median of 78 across 3,120 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

University of Glasgow is the lead sponsor of 145 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 25 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • having chronic inflammatory or disease, gastrointestinal complaints or known biliary obstruction (past and present)
  • use of anti-inflammatory drugs 2 weeks before the start of the study
  • use of antibiotics during the 12 weeks preceding the trial
  • pregnancy
  • lactation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Trial

    350 mg of BCM-95, 1 capsule per day, for 21 days.

    Dietary Supplement: BCM-95

  • Placebo comparator
    Control

    350 mg of starch, 1 capsule per day, for 21 days

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementBCM-95

    Consuming 1 capsule of BCM-95 per day.

    Also known as: Bio-Curcumin

  • Dietary supplementPlacebo

    Consuming 1 placebo capsule per day

06

What researchers measure

Primary outcomes

  1. Level of endotoxin in plasma.

    Time frame: 21 days

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03329781
Responsible party
Emilie Combet (Senior Lecturer, University of Glasgow) — Principal investigator
First posted
Nov 6, 2017
Start date
Feb 2015
Primary completion
Jan 2018
Completion
Jan 2018
Last update
Apr 30, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion